Clinical stage >= TNxM or TanyN+ disease for which radical or partial nephrectomy is planned Planned surgery or radiation therapy during protocol treatment Have a planned major surgery. Prior neoadjuvant chemo or biologic therapy for current breast cancer within weeks prior to planned surgery [Period ] Any other cancer treatments within weeks of planned study treatment Current, recent (within days prior to Day ), or planned use of any antitumor therapy outside this study Patients must have surgery planned to remove the desmoid tumor and either: Patients must be able to cooperate fully with all planned protocol therapy Planned procedure or surgery during the study Planned to receive Erbitux (Cetuximab) or similar targeted therapy between Baseline and weeks post-RT Patients who have received another cancer therapy within weeks before the planned day for the apheresis Patients who receive or are planned to receive any other investigational product within the weeks before the planned day for the first NKR- administration Last dose of AZA or DAC within months before the planned date of randomization; however, must be off these treatments for ? weeks before randomization Investigational therapy within weeks of planned randomization Patients receiving immunotherapy for non-cancer related treatment within < weeks of first planned dose of study treatment will be excluded. Prior (within last months) or future planned therapeutic surgery for the treatment of the existing lung cancer Current or planned glucocorticoid therapy, with the following exceptions: Patients who have the ability to collaborate planned follow-up Planned treatment with the LR-IUD for CAH or grade EC by primary physician Elective procedure (colectomy, gynecological, or thoracic) where at least one vessel is planned to be transected by the ENSEAL X device per its instructions for use; Patients who are receiving or are planned to start topical chemotherapeutics, retinoids or imiquimod to other lesions that are not planned for enrollment are eligible; however, the lesion being considered for enrollment should not be under active therapy with these topical agents immediately prior to enrollment.\r\n* Use of topical chemotherapeutics, retinoids or imiquimod on the lesion that is a candidate for enrollment must be halted at least hours prior to enrollment in the study. Planned vacation or dental work during the study phase Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes) Planned treatment site(s) accompanied by objective evidence of secondary radiculopathy or neurologic compromise Planned radiation treatments at Mayo Clinic Rochester Evidence of an infection within days of planned injection. Must have had a relapse or progressive disease (PD) after having received or more prior lines of systemic therapy. Note: A line of therapy is defined as or more cycles of a planned treatment program; this may consist of or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation (SCT), followed by maintenance is considered line of therapy. Typically each line of therapy is separated by PD. Subjects must be scheduled for surgery at Medical University of South Carolina (MUSC) no less than days from the planned start of day and no more than days from the planned start of day At the time of study enrollment, patients must have at least months of adjuvant trastuzumab planned Patients have planned invasive dental procedures during the course of the study Patients in which hemithoracic radiation therapy is planned Planned to get local surgery Planned goal TSH suppression .-. mU/L for at least weeks postoperatively Planned postoperative TSH goal different than .-. mU/L The parent study is closed or planned to be closed; and Planned use of maintenance or consolidative therapy Planned stereotactic body radiation therapy (SBRT) for the pulmonary metastases Planned pre-operative chemotherapy (patients with planned post-operative chemotherapy are eligible) Use of chemotherapy within weeks of the planned start of radiation therapy Planned treatment with TTFields therapy. Planned resectional surgery for MPM (extrapleural pneumonectomy [EPP] or pleurectomy and decortication [P/D]) No history of prior radiotherapy overlapping with high dose region of planned SABR course For patients with rHGG, the patient intends to undergo treatment with the Gliadel wafer at the time of planned resection (ie, on-study surgery) or has received the Gliadel wafer < days from the date of planned resection. Systemic chemotherapy delivered or planned to be delivered within (+/-) days of SRS re-irradiation Prior radiation therapy in the planned treatment field Patient can have prior SRS to lesions other than the one planned for neoadjuvant SRS and resection Planned concurrent WBRT Planned major surgery Planned use of Optune No planned systemic treatment is allowed within one week after treatment Planned IMRT (Intensity-Modulated Radiotherapy) Planned administration of cisplatin administered weekly or tri-weekly during RT Planned to receive concomitant single agent chemotherapy with cisplatin given either weekly or tri-weekly Planned neoadjuvant chemoRT treatment must conform to NCCN guidelines. Has received a T-cell product within weeks prior to planned infusion of genetically modified T cells. Patients planned for pre-operative chemotherapy or those with known metastatic breast cancer Patients with a planned use of Novo-TTF (Optune) are ineligible Planned invasive dental procedures during the course of study Planned major surgery during the study Planned radiation therapy after transplant No planned major surgery Planned major surgery Patients must have successfully completed therapy with sipuleucel-T within - days of planned CYT study drug treatment History of metastatic cancer diagnosed less than years prior to the first planned dose of PF- Patients with multiple, ipsilateral pulmonary nodules (T or T) are eligible if a definitive course of daily fractionated radiation therapy (RT) is planned Patients must have had either breast-conserving surgery with planned radiation therapy or total mastectomy (with or without planned postmastectomy radiation); patients must have clear margins from both invasive breast cancer and DCIS (as per local institutional guidelines); lobular carcinoma in situ (LCIS) at the margins is allowed Patients must not have received prior WBRT (previous SRS/SRT done at least weeks from the planned start of WBRT is acceptable); patients planned upfront to undergo SRS/SRT/fractionated boosts or neurosurgery after WBRT are not eligible; however, these treatments/procedures can be performed once the dose limiting toxicity (DLT) assessment has been completed, if felt clinically necessary Planned liver directed therapy or radiation therapy Patients whose entry to the trial will cause unacceptable clinical delays in their planned management The trial is open only to women with primary endometrioid adenocarcinoma of the uterine corpus (all histologic grades and stages) who are planned and appropriate for primary surgical treatment Breast surgery planned Current or planned use of systemic therapy for extracranial primary tumor Have a planned major surgery. Current or planned pregnancy within the next three months (females only) Reduction mammoplasty if DCRT or proton APBI are planned Chemotherapy < weeks prior to the first planned dose of study treatment Patients planned invasive dental procedures Intercurrent illness likely to prevent protocol therapy or conventional planned therapy Participants who relapsed from at least previous treatment AND additionally were refractory to at least previous treatment. For the purposes of this study, refractory disease was defined as disease progression on treatment or progression within days after the last dose of a given therapy. A line of therapy was defined as or more cycles of a planned treatment program. This may have consisted of or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance was considered line of therapy. Autologous and allogenic transplants were permitted. Women with planned treatment of primary definitive chemoradiation therapy Women with planned treatment of radiotherapy only (without chemotherapy) Chemotherapy given on the day of the planned radiotherapy treatment If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation therapy Planned first-line chemotherapy contains a proteasome-inhibiting agent administered weekly Change in chemotherapy agent is planned days before or after enrollment (change in dose(s) permitted), Major elective surgery to the spine in same region as the index vertebra(e) is planned within month following the ablation and cement procedure, Planned invasive dental procedure for the course of the study Planned to be treated by active surveillance Planned use of any treatment for PTCL during the course of the study. Has, at the planned initiation of study drug, an uncontrolled infection. Anti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of BBI/placebo within period of time equivalent to the usual cycle length of the regimen. An exception is made for oral fluoropyrimidines (e.g. capecitabine, S-), where a minimum of days since last dose must be observed prior to the first planned dose of BBI/placebo.Radiotherapy, immunotherapy, or investigational agents within four weeks of first planned dose of BBI/placebo, with the exception of a single dose of radiation up to Gray (equal to RAD) with palliative intent for pain control up to days before randomization. Macroscopic complete resection of the primary tumor must be planned Planned to receive standard cisplatin chemotherapy administered either weekly or every third week. Planned biopsy or resection of recurrent tumor for therapeutic and/or diagnostic purpose, and with adequate bone marrow, hepatic, cardiac, and renal function to undergo this planned procedure Planned invasive dental procedures for the course of the study. Planned initiation, termination, or dose alteration of hydroxyurea during the study Current or planned glucocorticoid therapy, with the following exceptions: Chemotherapy within weeks of first planned fraction of SBRT Planned invasive dental procedure for the course of the study Sarcomas where radiation is not planned preoperatively For stage I-III disease, patients should be - months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the -week study and no evidence of disease Beginning a new course of chemotherapy and/or immunotherapy (with a side effect profile that includes the symptoms monitored by SCH) that is planned for a minimum of three cycles Planned chemotherapy during radiosurgery Planned administration of bedside LR PLT transfusion(s) INCLUSION CRITERIA:\n\n . Subjects must be ? years old and have a life expectancy ? weeks\n\n . Histologically proven, primary (de novo) GB that has recurred or progressed (first or\n second recurrence, including this recurrence)\n\n . Confirmation that archived tissue is available from first diagnosis of GB for\n biomarker analysis\n\n . Recurrent tumor must be supratentorial, contrast-enhancing GB no smaller than cm x \n cm (largest perpendicular dimensions) and no larger than cm maximum in a single\n direction based on MRI taken within days prior to catheter placement\n\n . Karnofsky Performance Score (KPS) ? \n\n . Subjects must be able and willing to undergo multiple brain MRI examinations\n\n . Subjects must be able and willing to comply with all study procedures\n\n . Any related toxicities following discontinuation of prior GB therapies must have\n resolved to CTCAE Grade or lower prior to inclusion in this study\n\n EXCLUSION CRITERIA:\n\n . Prior treatment with cytotoxic chemotherapy\n\n . Temozolomide (standard induction and / or maintenance dosing) within the past \n weeks prior to planned infusion\n\n . \Metronomic\ Temozolomide (low-dose, continuous administration) within the past \n days prior to planned infusion\n\n . Nitrosoureas within the past weeks prior to planned infusion\n\n . Treatment with any other cytotoxic agent within the past weeks prior to planned\n infusion\n\n . Prior investigational treatment within the past weeks or prior immunotherapy or\n antibody therapy within the past weeks prior to planned infusion\n\n . Prior treatment with bevacizumab (Avastin) or other vascular-endothelial growth factor\n (VEGF) inhibitors or VEGF-receptor signaling inhibitors within the past weeks prior\n to planned infusion\n\n . Prior therapy that included interstitial brachytherapy or Gliadel Wafers (carmustine\n implants) within the past weeks prior to planned infusion\n\n . Prior surgery (including stereotactic radiosurgery and biopsy procedures) within the\n past weeks prior to planned infusion\n\n . Ongoing Optune therapy within days of planned infusion\n\n . Secondary GB (i.e., GB that progressed from low-grade diffuse astrocytoma or AA)\n\n . Known mutation in either the isocitrate dehydrogenase (IDH) or the IDH gene.\n\n . Tumor in the brainstem (not including fluid-attenuated inversion recovery [FLAIR]\n changes), an infratentorial tumor, diagnosis of gliomatosis cerebri (highly\n infiltrative T hyperintense tumor with ill-defined margins encompassing at least\n three lobes of the brain.\n\n . Tumor with a mass effect (e.g. - cm midline shift)\n\n . Subjects with tumors for which the preponderance of tissue is not of the type in which\n convection would be possible (e.g. preponderance of cystic component)\n\n . Tumor with geometric features that make them difficult to adequately cover the tumor\n volume with infusate by using CED catheters\n\n . Clinical symptoms that are thought by the Investigator to be caused by uncontrolled\n increased intracranial pressure, hemorrhage, or edema of the brain\n\n . Any condition that precludes the administration of anesthesia\n\n . Known to be human immunodeficiency virus positive\n\n . Concurrent or a history of any significant medical illnesses that in the\n Investigator's opinion cannot be adequately controlled with appropriate therapy or\n would compromise the subject's ability to tolerate the study drug therapy and/or put\n the subject at additional risk or interfere with the interpretation of the results of\n this trial\n\n . Known history of allergy to gadolinium contrast agents\n\n . Presence of another type of malignancy requiring treatment within < years prior to\n the screening visit, except for adequately treated carcinoma in-situ of the cervix,\n prostate cancer not actively treated, and basal or squamous cell carcinoma of the skin No planned reconstructive surgery with flap repair during trial and follow-up period No surgery planned in the next months Planned for bilateral axillary surgery Patient is planned to receive interventional procedures (i.e. surgery) that may affect study outcomes Treatment with antithymocyte globulin within days of planned infusion of virus specific, antigen selected T cells Treatment with virus specific T cells within weeks ( days) of planned infusion No surgery planned in the next months Primary treatment is active surveillance (AS) with planned annual surveillance biopsies Planned surgeries or radiation treatment within weeks following study inclusion Willingness to be followed for the planned duration of the trial ( years) Planned treatment with R-CHOP chemotherapy Known or suspected gynecologic or other abdominal malignancy (such as colorectal, liver, pancreatic, kidney and stomach) for which laparotomy is planned Planned less than two week hospitalization Planned participation in the Gynecologic Enhanced Recovery Pathway Treatment plan to receive a continuous course of IMRT delivered as single daily fractions of . to . Gy with a cumulative radiation dose between Gy and Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, tongue, soft palate) that are each planned to receive a total of > Gy. Patients who have had prior surgery are eligible, provided they have fully recovered from surgery, and patients who may have surgery in the future are eligible. No planned ostomy creation at time of enrollment Planned continuous antibiotic treatment during RT Planned surgery anticipated during the intervention period Abnormal global longitudinal strain (< %, or a % decrease of >= % from baseline) prior to initiation of planned anti-HER therapy Planned fractionated external beam radiotherapy to be delivered by opposing, tangential beams to . Gy in fractions with a planned photon or electron boost of Gy in fractions (for a total of fractions) Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization) Planned invasive dental procedures No planned surgery anticipated in the -month intervention period Patients with planned laparoscopic PD Planned stereotactic body radiation therapy (SBRT) Surgical intervention is planned primary mechanism of local control At least night of planned inpatient stay Planned total laryngectomy at Barnes Jewish Hospital (BJH) Planned outpatient surgery Women who are being seen at the Women's Health Center by the Gynecologic Oncology group at the University of Minnesota if planned surgery includes an exploratory laparotomy Patient receiving any investigational drug for hyperuricemia within days of planned first treatment with rasburicase Subjects who are planned to receive > mg flat dose of vinca alkaloids Patients who have been treated with chemotherapy or radiation within two weeks of planned study enrollment; this does not include hydroxyurea or ruxolitinib, which may be continued until start of conditioning therapy Planned cisplatin treatment restricted to the following treatment course criteria:\r\n* Dose: > mg/m^\r\n* Frequency: every (q)-q weeks\r\n* Cycles: maximum Planned concurrent administration of cisplatin chemotherapy (either mg/m^ every weeks or - mg/m^ every week) Split-course RT is planned Split-course RT is planned Planned continuous antibiotic treatment during RT Current or planned use of other agents for treating hot flashes Current or planned use of any type of antidepressants Not planned for surgical intervention EXCLUSION - PATIENT: Breast biopsy or surgical intervention planned before the test RSI-MRI in this study The patients planned cancer management is radiation to the liver with or without chemotherapy No recent or planned immunotherapy No future cancer therapy planned Participants need to have had a mammogram within days of day (normal/benign bi-rads or ) with no suspicion of a mass and no further routine breast imaging planned during the course of the study ( weeks) The patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, and there is a planned surgery for the primary colorectal cancer Prior or planned bariatric surgery At randomization, their planned course of antibacterial drug treatment for CDI is longer than days Current or planned pregnancy Men on stable doses of -alpha reductase inhibitors are eligible as long as there is no planned dose change while on study Current or planned pregnancy Has evidence of cancer at the time of enrolment, or has surveillance tests planned within weeks after enrollment Patient planned to receive altered fractionation radiotherapy or multiple fractions per day Pregnancy in the last months/planned within the next years or currently lactating Planned reconstructive surgery with flap repair during study period Planned partial breast radiation Planned use of ex vivo or in vivo T-cell depletion Subject is planned to undergo either of the following: Current or planned pregnancy within the next three months (females only) Planned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen. planned treatment course to include Cisplatin and radiation therapy, cumulative prescription dose between - Gy Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence; or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage < % AND clinical blood draw not planned; or patient sample did NOT already complete rapid heme panel leukemia profiling clinically Surgery/biopsy planned as part of clinical care that is anticipated to yield sufficient material to meet the minimum requirements for profiling; OR Prior RT is allowed and must have been completed more than days before planned study entry\r\n* Note: For re-irradiation cases, standard departmental guidelines should be followed so as to not exceed normal tissue Prior radiation therapy which would provide significant dose overlap with the planned target volume(s) delivered within days of enrollment or registration Cohort B only: (N = evaluable patients): Planned nephrectomy within weeks following protocol scan Planned administration of any NET therapy between scan and , except for short acting octreotide Men with prostate cancer and known bone metastases planned for new systemic therapy and/or radiotherapy and who have a planned clinically indicated staging multi-detector computed tomography (MDCT) Planned craniotomy and resection or biopsy Participant must be receiving a planned lymphoscintigraphy procedure Patients must have planned treatment with doxorubicin:\r\n* Patients with sarcoma must have an initial planned regimen including mg/m^ doxorubicin for at least cycles; NOTE: patients can be on additional chemotherapeutic agents \r\n* Patients with lymphoma must have an initial planned regimen including mg/m^of doxorubicin for at least cycles; NOTE: patients can be on additional chemotherapeutic agents\r\n* Patients with breast cancer must have an initial planned regimen including mg/m^ of doxorubicin for at least cycles; breast cancer patient enrollment will stop once breast cancer patients have been enrolled; NOTE: patients can be on additional chemotherapeutic agents Planned procedures or therapies in between SOC scans and study scan on s-DCT, e.g., biopsy or excision of lung lesion Planned thorascopic, robotic or laparoscopic surgical approach Subjects must be planned for resection (this includes localized resectable disease or patients with metastatic disease with planned palliative resection) and scheduled to begin neoadjuvant chemotherapy Patients must not be planned for lung resection after radiation therapy No international travel planned during the next months Planned quit date within the next two months Serum albumin must be planned to be collected after admission, but prior to treatment Previous exposure to OTL . Known FR-negative ovarian cancer . Planned surgical debulking via laparoscopy or robotic surgery, with no intent of laparotomy. Planned surgical approach via laparoscopy or robotic surgery